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Running headline: Glibenclamide Enhances Neurogenesis after MCAO 
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ABSTRACT  
Glibenclamide is neuroprotective against cerebral ischemia in rats. We studied whether 
glibenclamide enhances long-term brain repair and improves behavioral recovery after stroke. 
Adult male Wistar rats were subjected to transient middle cerebral artery occlusion (MCAO) 
for 90 min. A low dose of glibenclamide (total 0.6 µg) was administered i.v. 6, 12 and 24 h 
after reperfusion. We assessed behavioral outcome during a 30-day follow-up and animals 
were perfused for histologic evaluation. In vitro specific binding of glibenclamide to 
microglia increased after pro-inflammatory stimuli. In vivo glibenclamide was associated 
with increased migration of doublecortin-positive cells in the striatum toward the ischemic 
lesion 72 h after MCAO and reactive microglia expressed sulphonylurea receptor 1 (SUR1) 
and Kir6.2 in the striatum adjacent to the ventricle. One month after MCAO, glibenclamide 
also was associated with increased number of NeuN-positive and BrdU-positive neurons in 
the cortex and hippocampus, and enhanced angiogenesis in the hippocampus. Consequently, 
glibenclamide-treated MCAO rats showed improved performance in the limb-placing test on 
postoperative days 22 to 29 and in the cylinder and water-maze on postoperative test day 29. 
Therefore, acute blockade of SUR1 by glibenclamide enhanced long-term brain repair in 
MCAO rats, which was associated with improved behavioral outcome. 
 
Key Words: angiogenesis, microglia, neural stem cells, neuroprotection, regeneration and 
recovery, brain ischemia 
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INTRODUCTION 
The therapeutic potential of the administration of low doses of glibenclamide has been 
confirmed in different central nervous system (CNS) pathologies.1 Particularly, in 
experimental stroke models it reduces cerebral edema and infarct volume, and decreases 
mortality.2,3 In addition, this has been confirmed in stroke patients, where a retrospective 
study found that patients with diabetes mellitus taking glibenclamide that suffered an acute 
ischemic stroke had a better neurological outcome.4 
Glibenclamide blocks the sulphonylurea receptor 1 (SUR1), the regulatory subunit of the 
KATP-
5 and the NCCa-ATP-channels,
1,6 which under ischemic conditions are expressed in 
neurons, astrocytes, oligodendrocytes, endothelial cells1,7 and by reactive microglia.8 It has 
been proposed that the blockade of the astroglial NCCa-ATP-channel by glibenclamide prevents 
cytotoxic edema after cerebral ischemia.1,7 On the other hand, glibenclamide administration 
resulted in ameliorated reperfusion-derived oxidative stress and pro-inflammatory cytokine 
release in the rat hippocampus after cerebral ischemia in rats.9 In line with this, our previous 
study demonstrated that glibenclamide administration at 6, 12 and 24 hours after reperfusion 
caused early neuroprotection and this was accompanied by a better neurological outcome.8 
Although recently Simard et al10 showed an extended time window for glibenclamide 
treatment from 6 h to 10 h after onset of cerebral ischemia, and several studies point to a 
beneficial effect of glibenclamide to treat stroke, no previous studies have evaluated the long-
term effects of glibenclamide administration on brain repair and its correlation with 
functional outcomes after stroke.  
Our previous studies also showed that reactive microglia increase their expression of the 
KATP-channel components Kir6.1, Kir6.2, SUR1 and SUR2B after brain pathologies, and the 
in vitro pharmacology of the KATP-channel open state regulates the release of 
cytokines/chemokines.8,11,12 More precisely, glibenclamide increased the reactive 
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morphology, phagocytic capacity and TNF-α secretion of reactive microglia in vitro. Thus, as 
cerebral ischemia leads to an accumulation of microglia in the subventricular zone (SVZ), 
from where newly formed neuroblasts migrate towards the ischemic boundary zone,13 is 
likely that controlling the phenotype of activated microglia will promote brain repair. This 
will provide neuroprotection14 and pro-neurogenic mediators that support the different steps 
of neurogenesis.15,16 Indeed, stroke induces cortical neurogenesis in animals models,17,18 and 
more importantly, in the adult human brain.19,20 Whether microglia influence these processes 
and the fate of the newborn neurons is still unclear. Nonetheless, although there is 
contradictory evidence for microglia being pro-neurogenic, several recent findings reinforce 
the hypothesis that microglia can direct neurogenesis.16,21  
Thus, we hypothesized that early blockade of SUR1 by glibenclamide after cerebral 
ischemia enhances ischemia-induced neurogenesis in the striatum and long-term brain repair, 
thus leading to an improved functional outcome. To test this hypothesis we treated rats with 
low doses of glibenclamide i.v. early after focal cerebral ischemia and evaluated long-term 
neuroprotection, neurogenesis, angiogenesis and behavioral recovery. Next, to assess whether 
microglia could be involved in neurogenesis, we analyzed the expression in vivo of SUR1 by 
reactive microglia after ischemia and whether glibenclamide binds specifically to microglia 
using primary rat microglia cultures. 
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METHODS 
Transient Occlusion of the Middle Cerebral Artery in Rats  
Male Wistar rats (3 months old and weighing 250-300 g at the beginning of the study; 
National Laboratory Animal Centre, Kuopio, Finland) were used. They were kept on a 12 
h/12 h day and night cycle and housed individually with free access to food and water 
(20±1°C). Animals were handled following European legislation (86/609/EEC) and all efforts 
were made to minimize the number used and animal suffering, in accordance with the 
ARRIVE guidelines. The Animal Ethics Committee (Hämeenlinna, Finland) approved the 
study.  
Focal cerebral ischemia was induced by the intraluminal filament technique as described 
elsewhere.8 Briefly, the rats were anesthetized with 5% halothane (in 70% N2O/30% O2) and 
a surgical depth of anesthesia was maintained throughout the operation with 0.5 to 1% 
halothane delivered though a nose mask. The right common carotid artery was exposed 
through a midline cervical incision under a surgical microscope and gently separated from the 
nerves. A heparinized nylon filament (diameter 0.25 mm, rounded tip) was inserted into the 
stump of the external common carotid artery and advanced into the internal carotid artery 1.8-
2.1 cm until it blocked the blood flow into the middle cerebral artery. Corticostriatal damage 
was induced by an occlusion of the middle cerebral artery (MCAO) of 90 min and the blood 
flow was then restored by removing the filament.  Sham-operated control rats underwent the 
same procedure except that the filament was not inserted. To balance the MCAO groups the 
neurological symptoms were assessed before drug administration using two tests: 
contralateral rotation/circling behavior and impaired contralateral forelimb/hindlimb response 
to proprioceptive stimulus (i.e., lack of limb withdrawal when hanging over the edge of a 
table). Animals with no behavioral impairment were excluded from the study.  
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7 
Drug Treatment 
We divided 34 rats into the following three groups: sham-operated rats (n=10), vehicle-
treated MCAO rats (n=12) and glibenclamide-treated MCAO rats (n=12). Rats were placed 
in a restrainer for drug administration in the distal portion of the vein. Each rat received three 
injections of 0.2 ml of either 0.01 mol/L phosphate buffer saline (PBS; pH 7.4) or 0.2 µg 
glibenclamide into the tail vein 6, 12 and 24 h after reperfusion (total dose 0.6 µg). 
Glibenclamide was prepared in DMSO and diluted in 0.01 mol/L PBS to final concentration 
(DMSO final concentration <0.5%). In order to analyze cell proliferation we administered 
intraperitoneal injections of BrdU (50 mg/kg in PBS 50 mmol/L), with some modifications, 
as described elsewhere.22 In summary, all rats received a single injection of BrdU daily from 
postoperative days 4 to 8. Infarct volumes were measured at the end of the study and 
unsuccessful transient MCAO animals were excluded from the study (n=2 from vehicle 
group). 
 
Behavioral Outcome Measures 
Limb-PlacingTest 
The modified version of the limb-placing test23 was performed before operation and on 
postoperative days 2, 4, 7, 10, 13, 16, 19, 22, 26 and 29. The animals were habituated for 
handling and testing before the induction of ischemia. The test included seven limb-placing 
tasks to assess the integration of forelimb and hindlimb responses to tactile and 
proprioceptive stimulation. Briefly, animals were placed on the edge of a table and their 
forelimbs and hindlimbs were pushed over the edge to measure ability to retrieve their limbs. 
Tasks were performed from the front and the side of the rat, with and without the help of 
whisker stimuli. In addition, forepaw retraction was evaluated when the rat was lifted in the 
air by the base of its tail, and finally forepaw resistance was noted when the rat was pushed 
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on the table surface. Both sides of the body were tested to assess forelimb and hindlimb 
function. An observer blind to the experimental groups performed the behavioral analysis. 
Scoring: 2 points, normal response; 1 point, delayed and/or incomplete response; 0 points, no 
response.  
 
Forelimb Asymmetry Test 
The cylinder test was used to assess imbalance between impaired and non-impaired 
forelimbs.24 Briefly, the rats were placed in a Plexiglas cylinder (Ø 20 cm) for at least 4 min 
or until the rats were observed to rear a minimum of 20 times. Sessions were videotaped from 
below the cylinder and analyzed using a slow motion video recorder to determine the number 
of contacts by both forelimbs and by either impaired or non-impaired forelimbs. An observer 
blind to the experimental groups performed the behavioral analysis. The cylinder score for an 
impaired forelimb was calculated as: contralateral contacts/total contacts x 100 %. 
 
Tapered/Ledged Beam-Walking Test 
The sensorimotor function of hindlimbs was evaluated using a tapered/ledged beam.25 The 
beam-walking apparatus consisted of a tapered beam with underhanging ledges on each side 
to permit foot faults without falling and the end of the beam was connected to a black box. 
Steps onto the ledge were scored as a full slip and a half-slip was scored when the limb 
touched the side of the beam. The mean of three trials was used for statistical analyses. An 
observer blind to the experimental groups performed the behavioral analysis. Pretrained 
animals were tested in baseline conditions and on postoperative days 7 and 29. Performance 
was videotaped and analyzed by calculating the slip ratio (number of slips/number of total 
steps) of the impaired (contralateral to lesion) hindlimbs. 
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Morris Water-Maze 
Spatial learning was assessed using a modified version of the Morris water-maze task.23 Rats 
were given four trials per day on postoperative days 26 to 28 followed by the probe trial 
without the platform. The pool (Ø 150 cm) was divided into four quadrants or three annulus 
zones of equal surface area. Starting locations were called north, south, east, and west, and 
were located arbitrarily at equal distances along the pool rim. The platform was located in the 
middle of the northeast quadrant 25 cm from the pool rim. When the rat failed to find the 
hidden platform within 50 s, it was placed on the platform. The animal was allowed to remain 
on the platform for 10 s and to rest for 1 min after trials. The starting point was changed after 
each trial. The swim paths were monitored by a video camera connected to a computer 
through an image analyzer (HVS image). Escape latency (time to reach the platform) and the 
path length the animal swam to find the platform were parameters used to assess their 
performance in the water-maze task. Swimming speed (path length/escape latency) was 
calculated to exclude the effect of sensorimotor impairment. At the end of the third testing 
day, a 30 s probe trial without the platform was used to evaluate how well rats remembered 
the location of the platform (passes over the previous platform location). An observer blind to 
the experimental groups performed the behavioral analysis. Time spent in different annulus 
zones and quadrants of the pool was analyzed to examine the search strategies used by the 
animals. 
 
Immunohistochemistry  
Thirty days after MCAO, rats were anesthetized and transcardially perfused with saline for 5 
min, followed by 4% w/v paraformaldehyde in phosphate buffer. Brains were post-fixed, 
cryopreserved in 30% w/v sucrose and frozen on dry ice. Sections (14 µm) covering the 
entire brain were cut with a cryotome. 
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10
The first section between bregma +1.7 and +2.2 of each animal stained with standard 
Haematoxylin-Eosin (H&E) was selected at random. Sequential sections separated by 1 mm 
were selected for each animal to determine the total infarct volume using the optical 
microscope software AxioVision 4 AC (Zeiss) and applying the Cavalieri’s principle. This 
consisted of multiplying the infarct area by the distance between sections (1 mm) and 
combining the values from each section (5-6 sections/animal). The total infarct volume was 
calculated by subtracting the area of the remaining tissue in the ischemic hemisphere from 
the area of the intact contralateral tissue of each section.23 
Immunohistochemistry was carried out with the avidin-biotin peroxidase method as 
previously described.8 We used primary antibodies against doublecortin (DCX; clone C-18; 
1:150; Santa Cruz) to detect undifferentiated neurons and NeuN (1:150; Chemicon), 
calbindin (CB; 1:500; Swant), parvalbumin (PV; 1:2000; Swant), tyrosine hydroxylase (TH; 
1:5000; AbCam) or calretinin (CR; 1:2000; Swant) for differentiated neurons.26 To detect 
blood vessels we used RECA-1 (1:100; Serotec). For glial detection, we used antibodies 
against GFAP (1:400; Sigma-Aldrich), CD11b (OX-42 clone; 1:150; Serotec) or the isolectin 
B4 peroxidase-conjugated (IB4) from Bandeiraea simplicifolia (1:25; Sigma-Aldrich). We 
used an antibody against the sulfonylurea receptor 1 (SUR1; 1:100, Santa Cruz) to detect the 
glibenclamide target in microglial cells. The fate of the new proliferating cells was 
determined by double immunostaining with mouse monoclonal anti-BrdU antibody (1:100; 
Sigma-Aldrich) and biotin-conjugated rat anti-mouse IgG (1:150) and antibodies against 
specific cellular markers, as described elsewhere.26 ExtrAvidin-FITC (1:250; Sigma-Adrich) 
was used to detect BrdU-positive cells. Also, for immunofluorescence we used primary 
antibodies against NeuN (1:150; Chemicon), GFAP (1:400; Sigma-Aldrich), CD11b (OX-42 
clone; 1:150; Serotec) and caspase-3 (clone 5A1E; 1:500; Cell Signalling). Then we used 
specific anti-IgGs conjugated with AlexaFluo-488 (1:300; Invitrogen) to detect caspase-3 and 
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specific anti-IgGs from various species conjugated with AlexaFluo-555 (1:300; Invitrogen) 
for the other cellular markers. Confocal images were acquired using a Leica TCS SL laser 
scanning confocal spectral microscope (Leica Microsystems Heidelberg GmbH, Mannheim, 
Germany) and images were analyzed with ImageJ 1.39u (NIH, USA). 
Degenerating neurons were detected by Fluorojade B (FJB, Chemicon) fluorochrome, 
following the manufacturer’s instructions. 
Stereological methods were used to quantify the number of cells in the peri-infarct areas 
as described elsewhere.8 We applied the optical fractionator method to count labeled cells. 
Peri-infarct regions were outlined at cortical and subcortical levels at 2.5x magnification on 
arbitrary uniform random (AUR) coronal sections, located throughout the entire brain. 
Individual cells were viewed at 40x in AUR-sampled sites chosen by the Mercator Pro 7.0 
software (ExploraNova) and then counted.  
 
Cell Culture and Microglial Activation  
Cell culture procedures were approved by the Ethics Committee of the Universitat de 
Barcelona, in accordance with the regulations established by the Catalan autonomous 
government (Generalitat de Catalunya). Primary microglia-enriched cultures were obtained 
from post-natal-day-one rat brains, following the protocol described by Saura and colleagues 
27
, with slight modifications. Briefly, mixed glial cultures from post-natal-day-one rat brains 
were obtained from cerebral cortex and digested with 0.25% trypsin-EDTA solution 
(Invitrogen) for 30 min at 37ºC. Trypsinization was stopped by adding an equal volume of 
culture medium, consisted in Dulbecco’s modified Eagle medium-F-12 nutrient mixture 
(DMEM:F12, Invitrogen) supplemented with 10% FBS, 0.1% penicillin-streptomycin 
(Invitrogen), 0.5 µg/mL amphotericin B (Fungizone®, Invitrogen), and 0.04% 
deoxyribonuclease I (Sigma-Aldrich). Cells were pelleted (8 min, 1000 rpm), resuspended in 
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culture medium, and brought to a single cell suspension by pipetting vigorously and filtering 
through a 105 µm-pore mesh. Cells suspension were seeded at a density of 3·105 cells/mL 
and grown in a humidifier cell incubator containing 5% CO2 at 37ºC. Medium was replaced 
every 7 days. Microglial cultures were prepared by the mild trypsinization method after 19–
21 days in vitro (DIV), where mixed glial cultures were treated for 30 min with 0.06% 
trypsin-EDTA solution. That resulted in a 97%-enriched microglial culture. 
These microglial cultures were activated and treated 24 h after isolation as described 
below. Based on our preliminary results, cell cultures were pre-treated with 1 nmol/L 
glibenclamide diluted in culture medium (DMSO final concentration <0.05%; Sigma-
Aldrich, >99% purity).8 Thirty minutes later, cells were activated with 0.1 µg/mL of 
recombinant lipopolysaccharide (LPS) and 0.05 ng/mL of recombinant mouse interferon 
gamma (IFNγ; Sigma-Aldrich). After 48 h, cells were incubated for 30 min at 37ºC in HBSS 
and supplemented with 500 nmol/L glibenclamide–BODIPY-FL (green fluorescent dye; 
Invitrogen). After cell fixation with 4% w/v paraformaldehyde, we performed 
immunocytochemical analyses with mouse anti-rat CD11b (OX-42 clone; 1:500; Serotec) 
antibody and goat anti-mouse AlexaFluor-555 as a secondary antibody (1:500; Molecular 
Probes). Cultures were directly observed in an AxioObserver Z1 (Carl Zeiss; GmbH, 
Germany) inverted microscope equipped with FluoUp and CoLoc image software 
(ExploraNova, La Rochelle, France) and recorded on a high sensitivity camera (RetigaEXi 
Fast 1394, QImaging). Image processing was performed using the method described by 
Jaskolski and colleagues.28 The purity of the cultures was 97±1% (n=4 cultures), as based on 
the number of CD11b-positive compared to the total number of cell nuclei stained with 
Hoescht33258 (Invitrogen; 0.1 μg/ml in PBS). 
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Statistical Analyses 
Statgraphics 5.0 (STSC Inc., Rockville, MD) and GraphPad Prism4 (La Jolla, CA, USA) 
statistical packages were used. In vitro and histological data and differences in the infarct 
volumes between vehicle controls and glibenclamide-treated MCAO rats were analyzed 
using ANOVA followed by post hoc test Least Significant Difference (LSD). When 
normality was not reached, we applied the Kruskall-Wallis test followed by the Mann-
Whitney U-test. Differences in the limb-placing scores between experimental groups were 
analyzed by the Mann-Whitney U-test. We used repeated measures ANOVA to analyze the 
beam-walking, cylinder and water-maze data for the overall group effect. Groups were then 
compared using one-way ANOVA followed by a post hoc test LSD. Probe trial data were 
tested by ANOVA followed by LSD. All values are presented as mean ± standard error of 
mean (SEM). P values <0.05 were considered significant.  
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RESULTS 
Infarct Size, Gliosis, Neurodegeneration and Apoptosis 
We analyzed the effects of glibenclamide in terms of lesion volume by histological methods 
30 days after MCAO. Quantification of the lesion volume of Hematoxilin-Eosin stained 
sectio s showed that there was no difference in infarct volume size between vehicle- and 
glibenclamide-treated MCAO rats (Figure 1 A). We then performed stereological 
quantification of the MCAO-induced neuronal loss in the peri-infarcted volume by NeuN 
immunohistochemistry. Stereological counting showed same number of NeuN-positive cells 
in the peri-infarct striatum (Figure 1 B), but higher number in the peri-infarct cortex of 
glibenclamide-treated MCAO rats (Figure 1 C, P<0.05). 
The pattern and cell density of microglia/macrophages (IB4-stained) and astrocytes 
(GFAP-immunopositive) in ischemic animals showed activation, as evidenced by their 
reactive morphology (Supplemental figure 1 C). In addition, when we quantified the overall 
staining and cell density for both markers, we found that glibenclamide did not modify 
MCAO-induced astrogliosis or microgliosis in the cortex (Supplemental figure 1 A, B).  
As hypoxia and ischemia causes neuronal death in the peri-infarcted region, and 
consequently, secondary neurodegeneration in other brain regions, we analyzed whether 
neurodegenerative processes were still active one month after MCAO by Fluoro-Jade B 
(FJB) staining. Only scattered FJB-positive neurons were detected in the thalamus 
(Supplemental figure 2 A). We also studied apoptosis using cleaved caspase-3 
immunohistochemistry. Cleaved caspase-3 staining did not co-localize with neurons (NeuN) 
or astrocytes (GFAP) (Supplemental figure 2 B, C). However, cleaved caspase-3 staining co-
localized with some cells expressing the microglial/macrophage marker CD11b in the peri-
infarct region (Supplemental figure 2 D). These results suggest that, one month after ischemia 
secondary neurodegenerative processes had completed.  
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Characterization of neuroblast migration and long-term neurogenesis 
We hypothesized that glibenclamide treatment could influence neurogenesis after stroke. 
Firstly, DCX-immunohistochemistry was carried out to detect neuroblasts in the striatum 
migrating towards the lesion core to a group of rats sacrificed three days after MCAO (Sham 
n=3; MCAO groups n=6). Results showed that sham-operated animals had all DCX-positive 
cells attached to the intact lateral striatum or migrating through the rostral migratory stream 
(RMS). Contrary, MCAO animals showed increased migration of neural progenitor cells 
toward the infarct striatum (Figure 2 A, B) as reported previously.13,22 Interestingly, we found 
more migrating neuroblasts in the striatum of glibenclamide-treated than in vehicle-treated 
MCAO rats (P<0.001, Figure 2 A, B). Neuroblast migration towards the infarct core in the 
striatum was still active 30 days after MCAO (Figure 2 C, D) and the migration pattern was 
not altered by glibenclamide administration. In line, microglia from the striatum adjacent to 
the ventricle became reactive after ischemia, but we did not observe a change in their 
morphology driven by glibenclamide treatment (Figure 2 A). 
Secondly, to detect cell proliferation we sacrificed a group of rats 30 days after MCAO 
(sham n=9; vehicle n=10 and glibenclamide-treated group n=12). Immunohistochemistry 
against BrdU showed that vehicle-treated MCAO rats had more BrdU-positive cells in the 
cerebral cortex (P<0.001) than sham-operated rats (Figure 3 A). Glibenclamide treatment 
increased the number of BrdU-positive cells in the cerebral cortex (P<0.001) and in the CA1 
pyramidal layer (P<0.05; glibenclamide vs. sham) (Figure 3 A). Then, using the same group 
of animals, we performed double immunohistochemistries to identify the cell lineage of 
proliferative cells (Figure 3 A, B). Quantitative results showed an increased number 
BrdU/NeuN-positive cells in the cerebral cortex in vehicle-treated MCAO rats (P<0.001) and 
this was further boosted by glibenclamide treatment (P<0.001; glibenclamide vs. vehicle-
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treated MCAO rats). A slight increase in the number of BrdU/NeuN-positive cells was found 
in the CA1 region and in the SGZ of the hippocampus, although this increase was not 
statistically significant compared to the vehicle group (P<0.05; glibenclamide vs. sham). In 
addition, the other neuronal population markers (e.g., parvalbumin, tyrosine hydroxylase, 
calbindin) were also analyzed, but did not co-localize with BrdU (data not shown). The 
number of BrdU/GFAP-positive cells increased in the cortex of vehicle-treated MCAO rats 
(P<0.001) (Figure 3 A, B), pointing to an astroglial proliferation caused by the lesion. Also in 
the cortex glibenclamide-treated MCAO rats showed increased astroglial proliferation 
(P<0.001) compared to sham-operated rats and vehicle-treated MCAO rats. We then analyzed 
macrophages/microglia proliferation, and we observed an increased number of BrdU/IB4-
stained cells in the cortex (P<0.001) and in the CA1 pyramidal layer (P<0.001) of MCAO 
rats (Figure 3 A, B). 
To study whether glibenclamide modifies the fate of the neuroblasts as they migrate 
through the RMS, we quantified the number of BrdU-positive cells in the olfactory bulb 30 
days after MCAO. No differences in the number of these cells were found between MCAO 
groups in the olfactory bulb (542±26 BrdU-positive cells/section for sham, 518±37 for 
vehicle-treated group and 580±28 for glibenclamide-treated group). As the total number of 
proliferative cells in the olfactory bulb is not modified by ischemia or glibenclamide, the 
most likely the fate of neuroblasts migrating through the RMS is also unaffected. Therefore, 
these results indicate that glibenclamide strengthens intrinsic neurogenic processes as higher 
numbers of NeuN/BrdU-positive cells were found in the cortex. 
 
Angiogenesis 
To assess another brain repair mechanism, we studied angiogenesis in several brain regions 
by measuring vessel diameter and RECA-1 immunoreactivity 30 days after ischemia.29 The 
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diameter of vessels increased in the ipsilateral cortex of glibenclamide-treated MCAO rats 
(Figure 4 A, C). Quantitative analysis of RECA-1 immunoreactivity showed increased 
microvessel density in the ipsilateral hippocampus of glibenclamide-treated MCAO rats 
(Figure 4 B, C; P<0.01). This difference was not detected in the peri-infarct cortex, although 
a slight increase was found. 
 
Recovery of Sensorimotor and Cognitive Functions 
The effects of ischemia and glibenclamide treatment in the recovery of sensorimotor and 
cognitive functions were analyzed using a battery of behavioral tests during a 30 days follow-
up period. Spontaneous forelimb use was analyzed by the cylinder test (Figure 5 A). ANOVA 
for repeated measures showed an overall group effect (P<0.05), but no significant group x 
time interaction, thereby indicating that forelimb use differed between groups. A post hoc 
analysis revealed that forelimb use between sham-operated and vehicle-treated MCAO rats 
was different (P<0.05), but not between sham-operated and glibenclamide-treated MCAO 
rats. Forelimb use in the MCAO groups was different from that in sham-operated rats on 
postoperative day 7 (P<0.01). Impaired forelimb use in MCAO rats treated with 
glibenclamide was recovered and these animals showed similar performance to that of sham-
operated rats at the end of the follow-up period. 
We then used the limb-placing test to further analyze recovery of the forelimb function. 
All ischemic animals presented initial severe impairment in the limb-placing test after 
MCAO, followed by spontaneous recovery during the 29-day follow-up (Figure 5 B). Limb-
placing scores between sham-operated and MCAO rats were different in all post-operative 
time points (P<0.01). MCAO rats treated with glibenclamide showed an improved score 
compared to the vehicle group on postoperative days 22 to 29 (P<0.05; P<0.01).  
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The effect of glibenclamide on recovery of hindlimb function in MCAO rats was 
analyzed by tapered/ledged beam-walking. ANOVA for repeated measures showed an overall 
group effect (P<0.01) and a group x day interaction (P<0.01). However, there was no 
difference between glibenclamide-treated and vehicle-treated MCAO rats (p=0.81) (data not 
shown). 
Results from the Morris water-maze on post-operative days 26 to 28 showed that escape 
latency, length and swimming speed did not differ between groups. No significant differences 
were observed in the number of passes over the removed platform or the time rats spent in the 
target quadrant (probe trial). However, a thigmotaxis behavior was observed in vehicle-
treated MCAO rats, which they spent more time in the outermost zone (zone 3; P<0.05) and 
less time in the middle zone (zone 2; P<0.01) compared to sham-operated animals (Figure 5 
C-D). The search strategy in glibenclamide-treated MCAO rats was similar to that of sham-
operated animals.  
 
Glibenclamide Binds to Reactive Microglia 
To assess whether microglia express the KATP-channel components after ischemia, we 
performed double immunohistochemical labeling against SUR1 and Kir6.2 combined with 
the microglia/macrophage marker CD11b. Co-location of striatal CD11b-positive cells 
adjacent to the ventricle indicated that the reactive microglia of MCAO animals expressed the 
KATP-channel components SUR1 and Kir6.2 at 72 h after ischemia (Figure 6 A). To 
determine the specificity of binding to SUR1 expressed by microglia, we analyzed the 
binding of fluorescently tagged glibenclamide (glibenclamide BODIPY FL; green 
fluorescence) in primary rat microglial cultures. When microglial cells were in the resting 
state, glibenclamide labeling was localized to the perinuclear space (Figure 6 B). Forty-eight 
hours after LPS+IFNγ activation, glibenclamide-labeling was present in the plasmalemmal 
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membrane, denoting a translocation of SUR1 from its internal reservoir towards the cell 
surface. 
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DISCUSSION 
Previous preclinical and clinical data suggest a neuroprotective role for glibenclamide after 
cerebral ischemia.3,4 Here we showed that glibenclamide also enhanced early migration of 
neuroblasts towards the striatal lesion core and facilitated long-term brain repair in MCAO 
rats. Interestingly, this was associated with improved behavioral recovery.  
After a stroke, massive necrotic or apoptotic processes are activated in the ischemic core, 
as well as in distal regions due to Wallerian neurodegeneration. In our model we only 
observed a few scattered FJB positive neurodegenerative cells, which were mainly located in 
the thalamus one month after ischemia. In addition, the only cells labeled by cleaved caspase-
3 in the peri-infarct zone were some microglia/macrophages. Recent data demonstrated that 
cleaved caspase-3, a known mediator of apoptosis, regulates microglial activation by a non-
apoptotic pathway.30 Thus, we here found that one month after ischemia the majority of 
secondary neurodegenerative processes have been completed and caspase-3 positive 
microglia/macrophages may be participating in the tissue repair response to injury instead of 
undergoing apoptosis. Although glibenclamide did not reduce the size of the infarct, our 
results are in line with Simard et al,10 confirming that some factor other than infarct volume 
here also determined the long-term functional recovery outcome. Interestingly, in the Morris 
water maze task we observed thigmotaxis behavior in vehicle-treated MCAO animals (i.e., 
swimming close to the walls of the tank), which was decreased after glibenclamide treatment. 
However, whether thigmotaxis is related to cognitive or noncognitive strategies, or 
hippocampus-derived increases in stress or anxiety, still remain open.31,32 Thus, from our data 
we cannot rule out the possibility that glibenclamide, instead of improving cognitive 
outcome, ameliorates stress or anxiety caused by ischemia. It is noteworthy to mention here 
that our approach for glibenclamide administration is different to that used by Simard et 
al,3,7,10 who administered an intraperitoneal loading dose of 10 µg/kg plus a subcutaneous 
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infusion dose of 200 ng/h using an osmotic mini-pump. We administered glibenclamide 
intravenously with a dose of 0.8 µg/kg beginning 6 hours after onset of ischemia during the 
first 24 hours. The facts that the subunit SUR1 has a particularly high affinity for 
glibenclamide,33 the ischemic brain shows preferential uptake for glibenclamide7,8 and that 
we here use intravenous glibenclamide administration instead of subcutaneous infusion, 
could explain our results. However, the dose of glibenclamide was lower than the doses used 
in previous studies.  
Focal cerebral ischemia promotes neurogenesis in the SVZ and the SGZ of the dentate 
gyrus and induces neuroblast migration towards the striatal ischemic boundary.13,22 Recent 
data have provided new evidence that the cerebral cortex also has the same capacity,17 and 
more importantly, stroke-induced cortical neurogenesis has also been found in the adult 
human brain.19,20 In the present study, ischemia increased neuroblast migration towards the 
lesion 3 days after ischemia/reperfusion and this event persisted for up to one month. 
Inhibition of SUR1 using glibenclamide led to a further increase in the number of migrating 
neuroblasts, thereby indicating that glibenclamide modifies the cell lineage choice or 
enhances progenitor cell proliferation and migration.  
Proliferative cells detected by administration of BrdU from days 4 to 8 after 
ischemia/reperfusion showed increased co-expression of NeuN in the peri-infarct area of the 
cortex 30 days after reperfusion and this was potentiated by glibenclamide. Although we 
cannot exclude the possibility that some neural progenitors migrate from the SVZ to establish 
themselves in the ipsilateral cortical network, we found no co-localization of BrdU-positive 
cells with the classical RMS derived neuronal markers (i.e., calbindin, calretinin, tyrosine 
hydroxylase, parvalbumin) and no change in the total number of proliferative cells in the 
olfactory bulb. Thus, these newborn cortical neurons may have originated from potential 
resident neural stem cells within the cortex.17 Several authors have proposed that these 
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endogenous quiescent neural stem cells are present in the cerebral cortex and that their 
proliferation and differentiation to mature neurons is induced by ischemic insults.18 Although 
the number of these cells may be small, strategies to foster their intrinsic neurogenic potential 
would be highly relevant for clinical approaches to facilitate neural repair and functional 
recovery.  
Another purpose of this study was to investigate angiogenesis after cerebral infarction, 
because angiogenesis is also activated after cerebral ischemia. Generally, tissue repair is 
activated at 2 to 3 days after reperfusion, and the infarction is eventually encircled by a glial 
scar a few weeks later. As the glial response, in terms of the reactive area or cell density, was 
not modified by glibenclamide, we analyzed the microvessel diameter and the surface density 
as a parameter to quantify angiogenesis.29 We herein demonstrated that glibenclamide causes 
microvascular changes, where interestingly, glibenclamide further increased the diameter of 
microvessels in the non-lesioned cortex and RECA-1 immunoreactivity in the hippocampus, 
and both regions showed glial proliferation. These observations are consistent with those of 
Fantin and colleagues,34 who reported that tissue macrophages/microglia are associated with 
angiogenesis in various developing organs. Vasculature attracts microglial cells and 
stimulates them to release angiogenic factors,35 with subsequent growth stimulation of neural 
stem cells.36 Furthermore, angiogenesis is considered a key feature of ischemic stroke 
recovery and neuronal post-stroke re-organization.37  
Several studies using experimental stroke models have indicated the beneficial effects of 
glibenclamide administration after reperfusion, such as reversing ischemia-reperfusion injury 
by halting oxidative stress and inflammation in the hippocampus,9  preventing cytotoxic 
edema after cerebral ischemia2,3,1,7 and enhancing neuroprotection, which all eventually lead 
to a better functional outcome.8 Thus, although glibenclamide did not modify the size and 
cell density of microglia nor astroglia after ischemia here, it enhanced long-term brain repair 
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processes and functional recovery outcomes of the rats. We recently reported that 72 h after 
MCAO, activated microglia/macrophages in the ischemic hemisphere increase KATP-channel 
expression, and so does the murine microglial BV2 cell line 48 h after inflammatory stimuli.8 
We have now confirmed these results in postnatal primary rat microglial cultures. When 
microglial cells became activated after pro-inflammatory stimuli, they showed higher specific 
glibenclamide-labeling and the signal extended to the plasmalemmal membrane in vitro, 
pointing towards a mobilization of SUR1 from its internal reservoir in the endoplasmic 
reticulum and Golgi apparatus, towards the cell surface. Also, reactive microglia located in 
the lateral striatum 72 hours after MCAO expressed the KATP-channel components SUR1 and 
Kir6.2. All these results suggest that after microglial activation, KATP-channel expression is 
increased and the channel becomes translocated to the cell surface where it can exert its 
function in brain pathologies. In vitro glibenclamide regulates microglial phagocytic activity 
and the release of cytokines/chemokines after pro-inflammatory stimuli.8,11 As postnatal and 
adult microglia constitutively express low levels of SUR1,8,11,12 it is likely that regardless of 
the age of the animal the expression of SUR1 is upregulated by cell death/damage signals. 
Nonetheless, although glibenclamide possibly also blocks the SUR1 subunits of KATP- or 
NCCa-ATP-channels expressed in neurons, astrocytes and capillary endothelial cells,
2,3 there is 
increasing evidence that microglia participate in modifications of stem cell proliferation, 
migration and/or differentiation by producing trophic factors and inflammatory 
cytokines/chemokines.15,16 Thus, as microglial activation is a dynamic and complex 
process,38 the pro- or anti-neurogenic niche would depend on the degree of microglial 
activation and the balance between the pro- and anti-inflammatory soluble cytokines 
produced, without cell-cell contact required to direct this effect.16,21 In this scenario, it is 
possible that the interaction of glibenclamide with SUR1 endows microglia from the lateral 
striatum to carry a distinct phenotype that releases soluble factors with paracrine effects, 
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which consequently enhance neurogenesis and the migration of neuroblasts towards the 
lesion. 
In summary, we have demonstrated here that early blockade of SUR1 by glibenclamide 
produces long-term cortical neuroprotection, stimulates neuroblast migration towards the 
striatal lesion and strengthens neurogenesis in the cortex after cerebral ischemia. All these 
results were temporally associated with improved long-term behavioral recovery. Therefore, 
these data identify SUR1 as a multifaceted target that promotes both long-term 
neuroprotective processes and brain repair mechanisms. Further experiments are necessary to 
identify the specific role of the microglial KATP-channel and its diffusible mediators that may 
modulate brain repair, which will help us to shed light on the understanding of the intricate 
mechanisms underlying neurogenesis and neuroprotection after stroke caused by 
glibenclamide treatment. 
 
Disclosures 
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Supplementary information is available at the Journal of Cerebral Blood Flow and 
Metabolism website – http://www.nature.com/jcbfm 
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Titles and Legends to Figures 
 
Figure 1. Glibenclamide does not affect corticostriatal infarct size in MCAO rats (A). 
Quantification of NeuN-positive cells in the peri-infarct striatum (B) and cortex (C). Results 
are mean±SEM (n=10-12). *P<0.05 (compared with vehicle-treated MCAO rats). 
 
Figure 2. Glibenclamide enhances neuroblast migration towards the ischemic lesion. 
Representative micrographs of doublecortin (DCX) and microglia/macrophage (IB4) 
immunostaining in the striatum adjacent to the ventricle of sham-operated rat and vehicle- 
and glibenclamide- (Gbc, 0.6µg) treated MCAO rats three days after ischemia (A). 
Quantitative analysis of the migrating neuroblasts/section toward the cadoputamen lesion (B). 
Coronal section representation of an ischemic rat brain (bregma -0.8), where dark pink 
denotes for the necrotic core, light pink for peri-infarct area and green for healthy tissue (C). 
Enlarged image of the blue box from the left, in which DCX-positive cells (red) were still 
present in the peri-infarct striatum 30 days after MCAO (asterisk denotes the striatal lesion 
core) (D). Results are mean±SEM (n=3-6). ***P<0.001 (compared with sham rats); 
###
P<0.001 (compared with vehicle-treated MCAO rats). Bar=50 µm. 
 
Figure 3. Characterization of proliferative cells into the ischemic brain. Quantitative 
analysis of the total number of BrdU-positive cells/section and relative number of neurons 
(NeuN), astrocytes (GFAP) and microglia (IB4) double stained BrdU-positive cells in the 
cortex, CA1 pyramidal cell layer and subgranular zone (SGZ) (A). Confocal 
photomicrographs of the rat cortex showing colocalization of BrdU (in green) with NeuN, 
GFAP and IB4 (red) (B). Glibenclamide increased the total number of BrdU-positive cells 
after MCAO. These cells preferentially co-localized with markers of neurons and astrocytes. 
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Bar 10 µm. Results are mean±SEM (n=9-10). *P<0.05 (total BrdU-positive cells compared 
with sham rats); #P<0.05 (total BrdU-positive cells compared with vehicle-treated MCAO 
rats); ++P<0.01,+++P<0.001 (cell type compared with sham rats); &&P<0.01, &&&P<0.001 (cell 
type compared with vehicle-treated MCAO rats).  
 
Figure 4. Glibenclamide foster angiogenesis in the cortex and hippocampus of ischemic 
animals. Quantitative analysis of the microvessel diameter (A) and RECA-1 
immunoreactivity (B) in the cortex and hippocampus after MCAO. Glibenclamide 
administration increased microvessel diameter in the non-lesioned cortex and RECA-1 
immunoreactivity in the hippocampus. Representative micrographs of RECA-1 
immunoreactive microvessels in the cortex of sham-operated rat, vehicle- and glibenclamide-
treated (0.6µg) MCAO rats (C). Bar 50 µm. Results are mean±SEM (n=6-11). **P<0.01 
(compared to sham and vehicle-treated MCAO rats).  
 
Figure 5. Ischemic animals showed long-term improvement of neurological function 
after glibenclamide treatment. Contralateral forelimb use (cylinder test) (A) and limb-
placing scores (B) during a 29-day follow-up after MCAO. Swimming strategy in the probe 
trial test (Morris water-maze) on postoperative day 28 (C, D). Here the values are shown as a 
percentage of time spent in equal zones of the pool. Zone 1 refers to the inner annulus and 
zone 3 the outermost annulus. Results are mean±SEM (n=9-12). *P<0.05; **P<0.01 
(compared with sham-operated rats); #P<0.05; ##P<0.01 (compared with vehicle-treated 
MCAO rats).  
 
Figure 6. Reactive microglia express and translocate SUR1 to the cell surface. (A) 
Confocal photomicrographs of SUR1 and Kir6.2 (green) in reactive microglia (CD11b+; red) 
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localized to the striatum adjacent to the ventricle in MCAO rats. Yellow in the merge image 
denotes colocalization, whereby reactive CD11b-postive cells expressed SUR1 or Kir6.2 
seventy-two hours after ischemia. (B) Localization of glibenclamide (glibenclamide BODIPY 
FL; green fluorescence) in rat microglial primary culture. Non-activated or cultures activated 
with LPS+IFNγ for 48 h are shown in the upper row. Microglial cells were labeled with an 
anti-CD11b (red) antibody and Hoechst (blue) to stain the nuclei. Lower row shows 
respective colocalization of the red and green channels, where the yellow denotes the 
presence of the glibenclamide binding in microglial cells. Arrowhead denotes peri-nuclear 
colocalization and arrows show surface labeling; the data shown are representative of 4 
experiments each. Scale bar in (A) is 15 µm and in (B) is 20 µm. 
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Figure 1. Glibenclamide does not affect corticostriatal infarct size in MCAO rats (A). Quantification of NeuN-
positive cells in the peri-infarct striatum (B) and cortex (C). Results are mean±SEM (n=10-12). *P<0.05 
(compared with vehicle-treated MCAO rats).  
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Figure 2. Glibenclamide enhances neuroblast migration towards the ischemic lesion. Representative 
micrographs of doublecortin (DCX) and microglia/macrophage (IB4) immunostaining in the SVZ of sham-
operated rat and vehicle- and glibenclamide- (Gbc, 0.6µg) treated MCAO rats three days after ischemia (A). 
Quantitative analysis of the migrating neuroblasts/section toward the cadoputamen lesion (B). Coronal 
section representation of an ischemic rat brain (bregma -0.8), where dark pink denotes for the necrotic 
core, light pink for peri-infarct area and green for healthy tissue (C). Enlarged image of the blue box from 
the left, in which DCX-positive cells (red) were still present in the peri-infarct striatum 30 days after MCAO 
(asterisk denotes the striatal lesion core) (D). Results are mean±SEM (n=3-6). ***P<0.001 (compared with 
sham rats); ###P<0.001 (compared with vehicle-treated MCAO rats). Bar=50 µm.  
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Figure 3. Characterization of proliferative cells into the ischemic brain. Quantitative analysis of the total 
number of BrdU-positive cells/section and relative number of neurons (NeuN), astrocytes (GFAP) and 
microglia (IB4) double stained BrdU-positive cells in the cortex, CA1 pyramidal cell layer and subgranular 
zone (SGZ) (A). Confocal photomicrographs of the rat cortex showing colocalization of BrdU (in green) with 
NeuN, GFAP and IB4 (red) (B). Glibenclamide increased the total number of BrdU-positive cells after MCAO. 
These cells preferentially co-localized with markers of neurons and astrocytes. Bar 10 µm. Results are 
mean±SEM (n=9-10). *P<0.05 (total BrdU-positive cells compared with sham rats); #P<0.05 (total BrdU-
positive cells compared with vehicle-treated MCAO rats); ++P<0.01,+++P<0.001 (cell type compared with 
sham rats); &&P<0.01, &&&P<0.001 (cell type compared with vehicle-treated MCAO rats).  
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Figure 4. Glibenclamide foster angiogenesis in the cortex and hippocampus of ischemic animals. Quantitative 
analysis of the microvessel diameter (A) and RECA-1 immunoreactivity (B) in the cortex and hippocampus 
after MCAO. Glibenclamide administration increased microvessel diameter in the non-lesioned cortex and 
RECA-1 immunoreactivity in the hippocampus. Representative micrographs of RECA-1 immunoreactive 
microvessels in the cortex of sham-operated rat, vehicle- and glibenclamide-treated (0.6µg) MCAO rats (C). 
Bar 50 µm. Results are mean ± SEM (n=6-11). **P<0.01 (compared to sham and vehicle-treated MCAO 
rats).  
55x36mm (300 x 300 DPI)  
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Figure 5. Ischemic animals showed long-term improvement of neurological function after glibenclamide 
treatment. Contralateral forelimb use (cylinder test) (A) and limb-placing scores (B) during a 29-day follow-
up after MCAO. Swimming strategy in the probe trial test (Morris water-maze) on postoperative day 28 (C, 
D). Here the values are shown as a percentage of time spent in equal zones of the pool. Zone 1 refers to the 
inner annulus and zone 3 the outermost annulus. Results are mean±SEM (n=9-12). *P<0.05; **P<0.01 
(compared with sham-operated rats); #P<0.05; ##P<0.01 (compared with vehicle-treated MCAO rats).  
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Figure 6. Reactive microglia express and translocate SUR1 to the cell surface. (A) Confocal 
photomicrographs of SUR1 and Kir6.2 (green) in reactive microglia (CD11b+; red) localized to the striatum 
adjacent to the ventricle in MCAO rats. Yellow in the merge image denotes colocalization, whereby reactive 
CD11b-postive cells expressed SUR1 or Kir6.2 seventy-two hours after ischemia. (B) Localization of 
glibenclamide (glibenclamide BODIPY FL; green fluorescence) in rat microglial primary culture. Non-
activated or cultures activated with LPS+IFNγ for 48 h are shown in the upper row. Microglial cells were 
labeled with an anti-CD11b (red) antibody and Hoechst (blu ) to stain the nuclei. Lower row shows 
respective colocalization of the red and green channels, where the yellow denotes the presence of the 
glibenclamide binding in microglial cells. Arrowhead denotes peri-nuclear colocalization and arrows show 
surface labeling; the data shown are representative of 4 experiments each. Scale bar in (A) is 15 µm and in 
(B) is 20 µm.  
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